HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,163,262 | +29.2% | 292,232 | +23.6% | 0.03% | +26.9% |
| Q2 2023 | $8,639,250 | +3.0% | 236,368 | +7.6% | 0.03% | -3.7% |
| Q1 2023 | $8,386,409 | +51.9% | 219,597 | +61.8% | 0.03% | +107.7% |
| Q3 2021 | $5,521,000 | -10.0% | 135,726 | +0.4% | 0.01% | -18.8% |
| Q2 2021 | $6,137,000 | +13.3% | 135,148 | +4.0% | 0.02% | +6.7% |
| Q1 2021 | $5,416,000 | -4.3% | 129,923 | -1.9% | 0.02% | 0.0% |
| Q4 2020 | $5,657,000 | +63.0% | 132,450 | +0.3% | 0.02% | +25.0% |
| Q3 2020 | $3,470,000 | -36.5% | 132,049 | -35.2% | 0.01% | -42.9% |
| Q2 2020 | $5,465,000 | +56.9% | 203,820 | +5.3% | 0.02% | +10.5% |
| Q1 2020 | $3,483,000 | +42.9% | 193,619 | +40.9% | 0.02% | +46.2% |
| Q4 2019 | $2,437,000 | +398.4% | 137,428 | +336.1% | 0.01% | +333.3% |
| Q3 2019 | $489,000 | -9.6% | 31,512 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $541,000 | +5.0% | 31,512 | -1.5% | 0.00% | -25.0% |
| Q1 2019 | $515,000 | – | 31,997 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |